Mycobacterium leprae causes leprosy, a chronic infectious
disease. Hansen's disease is another name for leprosy. The skin, mucosal
surfaces of the upper respiratory tract, peripheral nerves, and eyes are all
affected. People of all ages, from infants to the elderly, can contract
leprosy. Although the actual method of transmission is unknown, it is widely
assumed that leprosy is transmitted from a leprosy patient to a healthy person.
Delayed leprosy diagnosis can lead to major problems like muscle weakness,
erectile dysfunction, kidney failure, blindness, and more. Avoiding contact
with infected and untreated patients is the greatest strategy to avoid
contracting leprosy. Leprosy is a treatable disease, and there are a variety of
medications on the market to treat it. Multidrug Therapy (MDT), which involves
the use of a mixture of medications, is one of the treatments for leprosy. For
leprosy therapy, the World Health Organization suggests combining rifampicin,
clofazimine, and dapsone medicines.
The Future of Leprosy Treatment Market
According to the World Health Organization (WHO), the number
of leprosy cases documented in 2015 was 176,176, or 0.18 cases per 10,000
persons, from diverse locations (138 countries). The number of new instances
demonstrates the disease's ability to spread over time. According to global
statistics, 22 significant nations were responsible for 203,600 (96%) of new
leprosy cases. The high occurrences prevalence serves as a reminder that some
parts of the world have significant disease incidence and transmission rates.
In the previous two decades, the World Health Organization estimates that
roughly 16 million cases of leprosy have been treated. On a global basis,
governing agencies and countries are attempting to eradicate the disease's
presence. The Leprosy
Treatment Market is predicted to increase at a significant rate
throughout the forecast period (2016–2024) because of these factors.
 |
Leprosy Treatment Market
Market Analysis for
Leprosy Treatment
Due to the growing patient pool of leprosy in Asia-Pacific,
the Leprosy Treatment Market is
predicted to rise at a breakneck pace over the forecast period. According to
the WHO, 176 instances per 10,000 persons were diagnosed with this disease in
2015. India is home to over 60% of the world's leprosy sufferers. As a result,
India is a key global market for this disease's treatment. Because
antibacterial medications are frequently prescribed by doctors for leprosy
treatment, the antibacterial category is predicted to gain the most market
share over the projection period. Dapsone, rifampin, clofazimine, ofloxacin,
and minocycline are some of the most frequent antibacterial medications used to
treat leprosy. Because of the increasing popularity of e-commerce around the
world, internet pharmacies are the fastest-growing distribution channel.
|
Comments
Post a Comment